Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
about
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patientsTargeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesThe endocannabinoid system as an emerging target of pharmacotherapyHigh Times for Painful Blues: The Endocannabinoid System in Pain-Depression ComorbidityCannabinoid and opioid interactions: implications for opiate dependence and withdrawalCannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury painInvolvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociceptionA systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain.Cannabinoid-opioid interactions during neuropathic pain and analgesia.Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors.Distribution of CB1 cannabinoid receptors and their relationship with mu-opioid receptors in the rat periaqueductal grayImpact of cannabis use during stabilization on methadone maintenance treatmentEmerging strategies for exploiting cannabinoid receptor agonists as medicines.Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids.Review article: dexmedetomidine: does it have potential in palliative medicine?The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.The analgesic effect of different antidepressants combined with aspirin on thermally induced pain in Albino miceNeonatal DSP-4 treatment modifies antinociceptive effects of the CB1 receptor agonist methanandamide in adult rats.Opioid and cannabinoid synergy in a mouse neuropathic pain model.Combination Drug Therapy for Pain following Chronic Spinal Cord Injury.Regulatory roles of the NMDA receptor GluN3A subunit in locomotion, pain perception and cognitive functions in adult mice.Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats.Effects of morphine/CP55940 mixtures on an impulsive choice task in rhesus monkeys.
P2860
Q24186716-5DD01577-D931-48D2-B105-7EC34E5343D7Q24623282-AA1BBE96-9C40-45E7-BCED-9357D01BC61BQ24648473-62F36566-7B7B-4260-A474-B80EC83BE0FAQ26784030-2D827A89-07E0-4F52-86BA-D08B4A08B927Q27000762-F43A9AB0-4FFE-4FA6-AD46-10D421A2910AQ28575056-1466E5CB-2EEF-4A9B-BD8B-2343DD44F1C8Q29395820-82CABFBF-CCA0-4878-A17A-EDDEFDF82D96Q30238997-E12D0E87-0F8C-4C25-9E66-F40282A846BBQ33637224-CCA4EDC7-6B92-40C4-B08E-BA1ADF98B434Q33715462-F4017A77-F86E-4F41-A385-49D72B422778Q36007619-348D2291-28A4-46FC-8475-F29A4209D963Q36476801-B3429811-1880-4476-B038-08677C444635Q37230665-C6E6F8BC-1215-4543-B3E2-BE5E1D3F9929Q37299577-4A01D990-6278-42DB-9DFF-D3F898223E28Q37345505-90DF4123-B89D-4E5D-AE18-891A772CD9E4Q37360643-2B40F785-7B09-49AE-9B5E-B62863C6F51FQ37371095-E7BD6EF4-72C9-4333-8353-785573FE92DFQ37646423-34CF18CE-BFB8-4D55-B589-C551F7618478Q37816062-8E1274F2-405E-4552-9F20-76F4D090A3CAQ38600704-D32B707D-9132-4D99-AA73-55E0E54CCDAEQ38694552-BD08589F-74AD-4864-8FBA-EF82D9ACC189Q39192669-2D19FF69-F3D2-415E-AACD-678178402CA8Q39248730-B0BEE14D-23BF-440D-99DE-59ADFED1206CQ42108639-ABBFDABF-C8BC-47D5-A55D-EB58EBC7971AQ42406036-6E75761B-F023-4D3A-9F92-FB86EFEB6CD0Q42548830-6239AA5D-77A0-4877-9766-444DB2FF4676Q44717304-7B76570B-706E-42C7-99B6-D6C256DB7B8BQ47777896-28407DD7-CAD6-46E5-94A4-4D647E1F6CE8Q48298041-7180FC23-4758-4933-AA4E-9B7305098B71Q49788551-163B66CE-64EE-4A83-B256-F6CDAEFB0CE8
P2860
Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Synergistic and additive inter ...... in acute pain models in mice.
@ast
Synergistic and additive inter ...... in acute pain models in mice.
@en
type
label
Synergistic and additive inter ...... in acute pain models in mice.
@ast
Synergistic and additive inter ...... in acute pain models in mice.
@en
prefLabel
Synergistic and additive inter ...... in acute pain models in mice.
@ast
Synergistic and additive inter ...... in acute pain models in mice.
@en
P2860
P50
P921
P356
P1476
Synergistic and additive inter ...... s in acute pain models in mice
@en
P2093
Shao M Tham
P2860
P304
P356
10.1038/SJ.BJP.0706045
P407
P577
2005-03-01T00:00:00Z